Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 5 results out of 5

Data Insights

VYD-2311 by Invivyd for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

VYD-2311 is under clinical development by Invivyd and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...

Data Insights

Pemivibart by Invivyd for Multiple Myeloma (Kahler Disease): Likelihood of Approval

Pemivibart is under clinical development by Invivyd and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pemivibart in Multiple Myeloma (Kahler Disease)

Data Insights

Pemivibart by Invivyd for Non-Hodgkin Lymphoma: Likelihood of Approval

Pemivibart is under clinical development by Invivyd and currently in Phase III for Non-Hodgkin Lymphoma. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Pemivibart in Non-Hodgkin Lymphoma

Data Insights

Pemivibart by Invivyd for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Pemivibart is under clinical development by Invivyd and currently in Phase III for Chronic Lymphocytic Leukemia (CLL). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pemivibart in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Pemivibart by Invivyd for Leukemia: Likelihood of Approval

Pemivibart is under clinical development by Invivyd and currently in Phase III for Leukemia. According to GlobalData, Phase III drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Pemivibart in Leukemia